Basic therapy for chronic non-infectious dermatoses of the anogenital region

Chronic non-infectious dermatoses of the anogenital area comprise a heterogeneous group of diseases characterized by varied etiopathogenesis, clinical manifestations, disease course, and prognosis. Treatment of dermatological conditions in the anogenital area often presents a complex challenge and necessitates an interdisciplinary approach. Traditionally, comprehensive therapy is employed, including agents aimed at restoring the cutaneous barrier, topical anti-inflammatory medications, particularly glucocorticosteroids and/or topical calcineurin inhibitors, and less frequently, systemic glucocorticosteroids, retinoids, hydroxychloroquine, or dapsone, as well as interventions targeting the alleviation of subjective symptoms and the prevention and treatment of secondary infections. The purpose of this publication is to discuss the fundamental aspects of baseline therapy for chronic non-infectious dermatoses of anogenital area. Baseline therapy is defined as a set of interventions that a patient with a dermatosis receives over a prolonged or continuous period, even during disease remission. Approaches to baseline therapy for dermatoses of anogenital area are poorly developed and require further clarification. Nevertheless, the regulation of the spectrum and quantity of agents used by the patient on the genital and perianal areas, the elimination of irritants, normalization of daily hygiene practices, and the use of agents that restore the cutaneous barrier are crucial components of comprehensive therapy for skin diseases in this anatomical location. One of the key aspects of successful treatment of dermatoses of anogenital area is the restoration of the cutaneous barrier, which can be disrupted by both the underlying disease processes and exposure to external factors. This article details the effects of preparations based on 5% dexpanthenol, which is regarded as a moisturizing and wound-healing agent. Dexpanthenol demonstrates significant anti-inflammatory activity, comparable to that of corticosteroids. Its use in therapy not only improves skin condition but also enhances the efficacy of cjrticosteroids, which is particularly important for patients requiring long-term management of dermatoses.

1. Lewin MR, Hick RW, Selim MA. Lichenoid Dermatitis of the Vulva: Diagnosis and Differential Diagnosis for the Gynecologic Pathologist. Adv Anat Pathol. 2017;24(5):278–293. https://doi.org/10.1097/PAP.0000000000000160.

2. Day T, Mauskar M, Selk A (eds.). Lichen sclerosus: ISSVD practical guide to diagnosis and management. Ad Médic, Lda.; 2024. 212 p. https://doi.org/10.59153/adm.ls.001.

3. Hong JJ, Mosca ML, Hadeler EK, Brownstone ND, Bhutani T, Liao WJ. Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management. Dermatol Ther. 2021;11(3):833–844. https://doi.org/10.1007/s13555-021-00536-6.

4. Corazza M, Toni G, Virgili A, Borghi A. Plasma cell vulvitis: further confirmation of the diagnostic utility of dermoscopy. Int J Dermatol. 2018;57(12):e164-e165. https://doi.org/10.1111/ijd.14233.

5. Yeung J, Pauls RN. Anatomy of the Vulva and the Female Sexual Response. Obstet Gynecol Clin North Am. 2016;43(1):27–44. https://doi.org/10.1016/j.ogc.2015.10.011.

6. Смирнова ИО (ред.). Неинфекционные дерматозы вульвы: диагностика, лечение: иллюстрированное руководство для врачей. М.: ГЭОТАР-Медиа; 2021. 240 с. https://doi.org/10.33029/9704-6008-5-NDV-1-240.

7. Nunns D, Mandal D. The chronically symptomatic vulva: prevalence in primary health care. Genitourin Med. 1996;72(5):343–344. https://doi.org/10.1136/sti.72.5.343.

8. Raef HS, Elmariah SB. Vulvar Pruritus: A Review of Clinical Associations, Pathophysiology and Therapeutic Management. Front Med. 2021;8:649402. https://doi.org/10.3389/fmed.2021.649402.

9. Neill SM, Lewis FM, Tatnall FM, Cox NH; British Association of Dermatologists. British Association of Dermatologists’ guidelines for the management of lichen sclerosus 2010. Br J Dermatol. 2010;163(4):672–682. https://doi.org/10.1111/j.1365-2133.2010.09997.x.

10. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. https://doi.org/10.1111/jdv.14891.

11. Lifits-Podorozhansky YM, Podorozhansky Y, Hoffstetter S, Gavard JA. Role of vulvar care guidelines in the initial management of vulvar complaints. J Low Genit Tract Dis. 2012;16(2):88–91. https://doi.org/10.1097/LGT.0b013e318232fd9a.

12. Lagro-Janssen AL, Sluis S. Effectiveness of treating non-specific pruritus vulvae with topical steroids: a randomized controlled trial. Eur J Gen Pract. 2009;15(1):29–33. https://doi.org/10.1080/13814780802705976.

13. Biro K, Thaçi D, Ochsendorf FR, Kaufmann R, Boehncke WH. Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebocontrolled study. Contact Dermatitis. 2003;49(2):80–84. https://doi.org/10.1111/j.0105-1873.2003.00184.x.

14. Proksch E, de Bony R, Trapp S, Boudon S. Topical use of dexpanthenol: a 70th anniversary article. J Dermatolog Treat. 2017;28(8):766–773. https://doi.org/10.1080/09546634.2017.1325310.

15. Murashkin NN, Materikin AI, Yepishev RV, Ambarchyan ET. Peculiarities of the Course and Prevention of Diaper Dermatitis in Newborns and Infants. Current Pediatrics. 2015;14(6):710–713. (In Russ.) https://doi.org/10.15690/vsp.v14i6.1481.

16. Peltier E, de Salvo R, Ehret A, Trapp S, Lakomsky D, El Shazly MA. Evaluation of a 5% dexpanthenol-containing ointment for the treatment of infant irritant diaper dermatitis through the lens of the caregiver-A real-world data observational study. Health Sci Rep. 2023;6(1):e1033. https://doi.org/10.1002/hsr2.1033.

17. Abiko Y, Tomikawa M, Shimizu M. Enzymatic conversion of pantothenylalcohol to pantothenic acid. J Vitaminol. 1969;15(1):59–69. https://doi.org/10.5925/jnsv1954.15.59.

18. Hrubša M, Siatka T, Nejmanová I, Vopršalová M, Kujovská Krčmová L, Matoušová K et al. Biological Properties of Vitamins of the B-Complex, Part 1: Vitamins B1 , B2 , B3 , and B5 . Nutrients. 2022;14(3):484. https://doi.org/10.3390/nu14030484.

19. Williams RJ, Saunders DH. The effects of inositol, crystalline vitamin B(1) and “pantothenic acid” on the growth of different strains of yeast. Biochem J. 1934;28(5):1887–1893. https://doi.org/10.1042/bj0281887.

20. Ebner F, Heller A, Rippke F, Tausch I. Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol. 2002;3(6):427–433. https://doi.org/10.2165/00128071-200203060-0000

21. Proksch E, Berardesca E, Misery L, Engblom J, Bouwstra J. Dry skin management: practical approach in light of latest research on skin structure and function. J Dermatolog Treat. 2020;31(7):716–722. https://doi.org/10.1080/09546634.2019.1607024.

22. Stettler H, Kurka P, Lunau N, Manger C, Böhling A, Bielfeldt S et al. A new topical panthenol-containing emollient: Results from two randomized controlled studies assessing its skin moisturization and barrier restoration potential, and the effect on skin microflora. J Dermatolog Treat. 2017;28(2):173–180. https://doi.org/10.1080/09546634.2016.1214235.

23. Björklund S, Pham QD, Jensen LB, Knudsen NØ, Nielsen LD, Ekelund K et al. The effects of polar excipients transcutol and dexpanthenol on molecular mobility, permeability, and electrical impedance of the skin barrier. J Colloid Interface Sci. 2016;479:207–220. https://doi.org/10.1016/j.jcis.2016.06.054.

24. Stettler H, Kurka P, Wagner C, Sznurkowska K, Czernicka O, Böhling A, et al. A new topical panthenol-containing emollient: skin-moisturizing effect following single and prolonged usage in healthy adults, and tolerability in healthy infants. J Dermatolog Treat. 2017;28(3):251–257. https://doi.org/10.1080/09546634.2016.1218417.

25. Udompataikul M, Limpa-o-vart D. Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol. 2012;11(3):366–374. Available at: https://pubmed.ncbi.nlm.nih.gov/22395588.

26. Ogorodova LM, Nagaeva TA, Hodkevich LV. The efficacy of dexpanthenol in the complex treatment of atopic dermatitis in children. Pediatric Pharmacology. 2003;1(3):54–56. (In Russ.) Available at: https://cyberleninka.ru/article/n/effektivnost-dekspantenola-v-kompleksnom-lecheniiatopicheskogo-dermatita-u-detey/viewer.

27. Кубанов АА, Аполихина ИА, Плахова КИ, Чернова НИ, Соколова АВ. Лишай склеротический и атрофический: клинические рекомендации. 2020.

28. Dukhanin AS. PH value of the base of topical drug product: the choice of the optimal value and the role of buffer system. Klinicheskaya Dermatologiya i Venerologiya. 2016;15(2):47–52. (In Russ.) https://doi.org/10.17116/klinderma201615247-52.

29. Ustinov MV. Empirical therapy of inflammatory lesion of large skin folds. RMJ. 2016;(14):945–948. (In Russ.) Available at: https://www.rmj.ru/articles/dermatologiya/Empiricheskaya_terapiya_vospalitelynyh_poragheniy_koghi_krupnyh_skladok

30. Macura AB. In vitro susceptibility of dermatophytes to antifungal drugs: a comparison of two methods. Int J Dermatol. 1993;32(7):533–536. https://doi.org/10.1111/j.1365-4362.1993.tb02844.x.

31. Arévalo MP, Carrillo-Muñoz AJ, Salgado J, Cardenes D, Brió S, Quindós G, Espinel-Ingroff A. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother. 2003;51(1):163–166. https://doi.org/10.1093/jac/dkg018.